INT210157

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.13
First Reported 2007
Last Reported 2007
Negated 0
Speculated 2
Reported most in Body
Documents 1
Total Number 7
Disease Relevance 1.50
Pain Relevance 0.10

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (TNFRSF8, TNFSF8) cell proliferation (TNFSF8) extracellular space (TNFSF8)
plasma membrane (TNFRSF8) cell-cell signaling (TNFSF8) cytoplasm (TNFRSF8)
Anatomy Link Frequency
HeLa 1
lymphocyte 1
TNFRSF8 (Homo sapiens)
TNFSF8 (Homo sapiens)
Pain Link Frequency Relevance Heat
Inflammation 56 75.92 Quite High
agonist 7 75.60 Quite High
cytokine 21 50.00 Quite Low
member 8 14 5.00 Very Low Very Low Very Low
rheumatoid arthritis 7 5.00 Very Low Very Low Very Low
Inflammatory response 7 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Lymphatic System Cancer 49 93.76 High High
Apoptosis 28 88.00 High High
Necrosis 14 81.48 Quite High
Cancer 14 81.12 Quite High
Infection 14 77.04 Quite High
INFLAMMATION 63 75.92 Quite High
Viral Infection 21 20.16 Low Low
Autoimmune Disease 7 9.12 Low Low
Leukemia 14 8.32 Low Low
Hypersensitivity 7 7.76 Low Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In the reduced state, CD30 lost its ability to interact with its cognate ligand CD30L or agonistic antibodies.
CD30 Binding (interact) of CD30L
1) Confidence 0.13 Published 2007 Journal EMBO J Section Body Doc Link PMC1914094 Disease Relevance 0.21 Pain Relevance 0.03
As shown by fluorescence microscopy, sCD30L binds to the surface of CD30-transfected HeLa cells and colocalizes with its receptor (Figure 6B, upper row).
CD30 Binding (binds) of sCD30L in HeLa
2) Confidence 0.10 Published 2007 Journal EMBO J Section Body Doc Link PMC1914094 Disease Relevance 0.22 Pain Relevance 0.04
To test whether Trx1-mediated reduction of CD30 influences binding of CD30 to its ligand (CD30L), we analyzed the interaction between CD30 and recombinant soluble CD30L (sCD30L) on the cell surface by flow cytometry.
CD30 Spec (analyzed) Binding (interaction) of sCD30L
3) Confidence 0.10 Published 2007 Journal EMBO J Section Body Doc Link PMC1914094 Disease Relevance 0.17 Pain Relevance 0
We demonstrate that disulfide exchange between Trx1 and CD30 interferes with binding of the CD30 ligand (CD30L) to its cognate receptor and that Trx1 affects CD30-dependent changes in lymphocyte effector function.
CD30 Binding (binding) of CD30L in lymphocyte
4) Confidence 0.10 Published 2007 Journal EMBO J Section Body Doc Link PMC1914094 Disease Relevance 0.40 Pain Relevance 0.04
To test whether Trx1-mediated reduction of CD30 influences binding of CD30 to its ligand (CD30L), we analyzed the interaction between CD30 and recombinant soluble CD30L (sCD30L) on the cell surface by flow cytometry.
CD30 Binding (binding) of CD30L
5) Confidence 0.10 Published 2007 Journal EMBO J Section Body Doc Link PMC1914094 Disease Relevance 0.16 Pain Relevance 0
To test whether Trx1-mediated reduction of CD30 influences binding of CD30 to its ligand (CD30L), we analyzed the interaction between CD30 and recombinant soluble CD30L (sCD30L) on the cell surface by flow cytometry.
CD30 Binding (binding) of CD30L
6) Confidence 0.08 Published 2007 Journal EMBO J Section Body Doc Link PMC1914094 Disease Relevance 0.16 Pain Relevance 0
To test whether Trx1-mediated reduction of CD30 influences binding of CD30 to its ligand (CD30L), we analyzed the interaction between CD30 and recombinant soluble CD30L (sCD30L) on the cell surface by flow cytometry.
CD30 Spec (analyzed) Binding (interaction) of CD30L
7) Confidence 0.08 Published 2007 Journal EMBO J Section Body Doc Link PMC1914094 Disease Relevance 0.17 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox